A Life Rewritten: Finding Strength in the Face of Melanoma
By Mara Klecker Just Normal People Asked to describe his life before the first melanoma diagnosis—before losing an eye, undergoing…
11/24/2025
A Life Rewritten: Finding Strength in the Face of Melanoma
By Mara Klecker Just Normal People Asked to describe his life before the first melanoma diagnosis—before losing an eye, undergoing…
|
11/20/2025
Living Through TIL Therapy: A Personal Story
By Mara Klecker A Hidden Threat Michael Moran initially assumed the rough patch on his left heel was simply a…
|
11/07/2025
You’re Not Out of Options: What to Do When First-Line Melanoma Treatment Fails
Melanoma treatment has advanced dramatically over the past decade, with immunotherapy and targeted therapies offering hope for many patients. However,…
|
11/06/2025
Honoring Veterans and Raising Awareness About Skin Cancer
On the eleventh hour of the eleventh day of the eleventh month in 1918, the armistice ended the fighting of…
|
11/06/2025
From Service to Survival: A Veteran’s Battle with Melanoma
by Mara Klecker When a bump appeared on the top of his head in 2018, retired Marine Corps Chief Warrant…
|
11/02/2025
From Knowledge to Action: Skin Cancer Prevention for Service Members
Introduction Members of the military experience greater morbidity and have a higher likelihood of experiencing skin cancer, and melanoma in…
11/02/2025
Immune Checkpoint Inhibition for Melanoma: A Focus on Veterans
Introduction Veterans have been shown to have a higher risk for melanoma compared to the general U.S. population due to…
|
11/02/2025
Overview of Melanoma in Veterans
Considerations Regarding Epidemiology, Risk Factors, Diagnosis, Prognosis, Survival, and Treatment Introduction Distinct health challenges affect veterans both during and after…
|
10/22/2025
SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma
Rotterdam, The Netherlands – San Diego, CA – [October 22nd] – SkylineDx today announced that results from its landmark MERLIN_001…
|
|
10/20/2025
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) — Replimune…
|
Recent Posts
Nov. 24, 2025
A Life Rewritten: Finding Strength in the Face of Melanoma
Nov. 20, 2025
Living Through TIL Therapy: A Personal Story
Nov. 07, 2025
You’re Not Out of Options: What to Do When First-Line Melanoma Treatment Fails
Nov. 06, 2025
Honoring Veterans and Raising Awareness About Skin Cancer
Nov. 06, 2025